Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion. (February 2023)

• Record Type: Journal Article
• Authors: Andrés, Cristina; González-Sánchez, Alejandra; Jiménez, Moraima; Márquez-Algaba, Ester; Piñana, Maria; Fernández-Naval, Candela; Esperalba, Juliana; Saubi, Narcís; Quer, Josep; Rando-Segura, Ariadna; Miarons, Marta; Codina, Maria Gema; Ruiz-Camps, Isabel; Pumarola, Tomàs; Abrisqueta, Pau; Antón, Andrés
• Is Part Of: Clinical microbiology and infection. Volume 29:Number 2(2023)
• Page Start: 240
• Page End: 246
• Publication Date: 2023-02
• Subjects: Immunocompromised -- Omicron -- Resistance -- SARS-CoV-2 -- Sotrovimab; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2022.08.021
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Objectives: To monitor the early emergence of genetic mutations related to reduced susceptibility to monoclonal anti-body (mAb)-based treatment in immunocompromised patients with long-term viral excretion using whole-genome sequencing at a tertiary university hospital in Barcelona, Spain. Methods: Serial severe acute respiratory syndrome coronavirus 2-positive samples (mid-December 2021–mid-March 2022) from eight immunosuppressed, fully vaccinated patients (for solid-organ transplantation or haematologic malignancies) with long-term viral excretion despite undergoing mAb therapy (sotrovimab) for coronavirus disease 2019 were selected. Whole-genome sequencing was performed following the ARTIC, version 4.1, protocol on the MiSeq platform. Mutations in the coding sequence of the spike protein with a frequency of ≥5% were studied. Results: A total of 37 samples from the studied cases were analysed. All the cases, except one, were confirmed to have the Omicron variant BA.1; one had Delta (AY.100). Thirty-four different mutations were detected within the receptor-binding domain of the spike protein in 62.5% of patients, eight of which were not lineage related and located in the sotrovimab target epitope (P337L, E340D, E340R, E340K, E340V, E340Q, R346T and K356T). Except for P337L, all changes showed a significant increase in frequency or fixation after the administration of sotrovimab. Some of them have been associated with either reduced susceptibility to mAb therapy, such as those at position 340, or the acquisition of a new glycosylation site (346 and 356 positions). Conclusions: This study highlights the importance of monitoring for early in vivo selection of mutations associated with reduced susceptibility to mAb therapy, especially in immunocompromised patients receiving anti-viral drugs, whose immune response is not able to control viral replication, resulting in long-term viral shedding, and those receiving selective evolution pressure. Virologic surveillance of genetically resistant viruses to available anti-viral therapies is considered a priority for both patients and the community.